ATNM:NYE-Actinium Pharmaceuticals, Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 10.40

Change

+0.05 (+0.48)%

Market Cap

USD 0.14B

Volume

0.34M

Average Target Price

N/A
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.93 (-1.36%)

USD156.25B 27.68 2.61
BHVN Biohaven Pharmaceutical Holdin..

-1.00 (-1.14%)

USD5.28B N/A N/A
ADCT ADC Therapeutics SA

-2.36 (-6.22%)

USD2.91B -99,999.99 N/A
ZYME Zymeworks Inc

-0.38 (-0.69%)

USD2.51B 300.20 N/A
MYOV Myovant Sciences Ltd

+0.93 (+3.96%)

USD2.13B N/A N/A
RCUS Arcus Biosciences, Inc

+0.85 (+3.13%)

USD1.76B N/A N/A
CVM CEL-SCI Corporation

-0.45 (-3.64%)

USD0.48B N/A N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
RFL Rafael Holdings, Inc

+1.19 (+5.63%)

USD0.33B N/A N/A
IBIO iBio, Inc

-0.07 (-4.40%)

USD0.29B N/A N/A

ETFs Containing ATNM

Symbol Name Weight Mer Price(Change) Market Cap
RJZ ELEMENTS Linked to the Ro.. 0.00 % 0.75 %

N/A

USD4.19M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 59.02% 73% C 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.02% 73% C 94% A
Trailing 12 Months  
Capital Gain 42.08% 63% D 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.08% 63% D 90% A-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.90% N/A N/A 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.90% N/A N/A 76% C
Risk Return Profile  
Volatility (Standard Deviation) 29.35% N/A N/A 22% F
Risk Adjusted Return 37.15% N/A N/A 53% F
Market Capitalization 0.14B 53% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.35 54% F 26% F
Price / Cash Flow Ratio -6.55 37% F 91% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -73.83% 52% F 5% F
Return on Invested Capital -292.59% 17% F 0% N/A
Return on Assets -38.51% 48% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.71 77% C+ 56% F
Short Percent 4.91% 56% F 47% F
Beta 1.18 70% C- 41% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.